RXi receives USPTO notices of allowance for certain siRNA sequence-specific patent applications

RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that Notices of Allowance were recently issued by the United States Patent Office (USPTO) on patent applications filed by Thermo Fisher Scientific Inc. and licensed to RXi Pharmaceuticals encompassing small interfering RNA (siRNA) sequences targeting superoxide dismutase (SOD1), Amyloid beta (A4) precursor protein (APP), interleukin-1 receptor-associated kinase 4 (IRAK4), hepatocyte growth factor receptor (MET protooncogene) and cyclin-dependent kinase (cdk) inhibitor p27 (also known as MET protooncogene).

These applications, which contain claims that cover specific siRNA sequences, are the first to have received notices of allowance by the USPTO of many patent applications encompassing siRNA sequences licensed by RXi from Thermo Fisher Scientific. These functional siRNA sequences were originally selected utilizing Thermo Fisher Scientific’s proprietary siRNA sequence selection algorithm, which was co-developed by Anastasia Khvorova, Ph.D., RXi’s Chief Scientific Officer, when she was previously at Thermo Fisher Scientific. RXi has obtained broad rights to these sequence-specific patent applications.

Tod Woolf, Ph.D. President and CEO of RXi Pharmaceuticals commented, “We are delighted that the US Patent Office has allowed a number of these siRNA sequence-specific patent applications to issue. These sequence-specific patent applications and the ones we expect to follow add another important component to our robust intellectual property portfolio, encompassing our advanced RNAi therapeutics and further enabling RXi to develop drugs for multiple indications and to build a sustainable pipeline of products for unmet medical needs.”

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Thermo Fisher Scientific Inc.. (2019, April 30). RXi receives USPTO notices of allowance for certain siRNA sequence-specific patent applications. News-Medical. Retrieved on May 25, 2019 from https://www.news-medical.net/news/20091003/RXi-receives-USPTO-notices-of-allowance-for-certain-siRNA-sequence-specific-patent-applications.aspx.

  • MLA

    Thermo Fisher Scientific Inc.. "RXi receives USPTO notices of allowance for certain siRNA sequence-specific patent applications". News-Medical. 25 May 2019. <https://www.news-medical.net/news/20091003/RXi-receives-USPTO-notices-of-allowance-for-certain-siRNA-sequence-specific-patent-applications.aspx>.

  • Chicago

    Thermo Fisher Scientific Inc.. "RXi receives USPTO notices of allowance for certain siRNA sequence-specific patent applications". News-Medical. https://www.news-medical.net/news/20091003/RXi-receives-USPTO-notices-of-allowance-for-certain-siRNA-sequence-specific-patent-applications.aspx. (accessed May 25, 2019).

  • Harvard

    Thermo Fisher Scientific Inc.. 2019. RXi receives USPTO notices of allowance for certain siRNA sequence-specific patent applications. News-Medical, viewed 25 May 2019, https://www.news-medical.net/news/20091003/RXi-receives-USPTO-notices-of-allowance-for-certain-siRNA-sequence-specific-patent-applications.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
TopoMAPS image analysis software now available on Thermo Scientific SEM and DualBeam systems